Ponasterone

Ponasterone: A Comprehensive Encyclopedic Reference

1. Identity and Chemical Characterization

1.1 Nomenclature

Ponasterone — most commonly encountered as Ponasterone A (PonA), the best-characterized member of the ponasterone series — is a naturally occurring polyhydroxylated sterol belonging to the ecdysteroid class of compounds. It is formally named 2β,3β,14α,20β,22R-pentahydroxy-5β-cholest-7-en-6-one and is structurally described as having five hydroxyl groups at positions 2, 3, 14, 20, and 22 on a cholestane backbone with a 7-en-6-one motif. It is also referred to in the literature as PonA, PoA, ponasterone A, and, in some older literature, as a phytoecdysone. The ponasterone series includes ponasterone A, ponasterone B, ponasterone C, and ponasterone D, though ponasterone A is overwhelmingly the most studied and biologically potent representative.

Ponasterone A has a molecular weight of 464.6 g/mol. It is distinguished from its close structural relative 20-hydroxyecdysone (20E) by a single key difference: it differs from 20E in lacking a single hydroxyl group at position 25. This seemingly minor structural difference carries substantial biological consequences, particularly in receptor-binding affinity.

1.2 Classification Within Ecdysteroids

Ecdysteroids are polyhydroxylated sterols that are widespread in the plant and animal world; to date, over 520 ecdysteroids have been isolated from natural sources. Compared to human steroidal hormones, ecdysteroids are more hydrophilic due to polyhydroxylation; they have C-27 to C-29 steroidal cores and different shapes due to an A/B-cis-ring conjugation. Their structural variations lie in the side chains linked to C-17 of the steroidal D-ring, methylation patterns, and conjugation moieties linked through the hydroxyl groups.

The ponasterones occupy a unique position within the ecdysteroid class: the ponasterones were the first ecdysteroids to be isolated from plants, in 1966. The credit for their discovery belongs to the Japanese chemist Koji Nakanishi and his group. The first phytoecdysone, ponasterone A, was discovered by Koji Nakanishi, and the identical molecule was later found in some crustaceans.

1.3 Natural Sources

Ponasterone A is found across a surprisingly wide taxonomic range, including both plants and animals.

Plant sources: Nakanishi et al. chemically investigated the leaves of Podocarpus nakaii (Podocarpaceae) and isolated three steroids named ponasterones A, B, and C. Concurrently, an Australian group reported the isolation of 20-hydroxyecdysone from the wood of Podocarpus elatus. Subsequent phytochemical surveys have confirmed that ponasterone A is not restricted to a single genus. Screening of Podocarpaceae and related plants has led to the isolation of ponasterone A from Podocarpus macrophyllus, P. chinensis, and Taxus cuspidata. More broadly, phytoecdysteroids have been identified in a wide range of organisms, including algae, fungi, ferns, gymnosperms, and angiosperms, with over 500 distinct compounds isolated from more than 100 terrestrial plant species. The most common phytoecdysteroids found in plants include 20-HE, ajugasterone C, turkesterone, polypodin B, and ponasterones A–C. In contrast to muristerone A, extracted from the rare kaladana seeds, ponasterone A can be purified from the leaves of many plants, including those of the Podocarpaceae family, a widespread conifer species. Ponasterone has additionally been reported from fern species, including being identified among the secondary metabolites of the fern Acrostichum aureum. The compounds 7,8β-dihydroponasterone A was isolated from Taxus cuspidata, and ponasterone A 20,22-p-hydroxybenzylidene acetal and ponasterone A 20,22-acetonide were isolated from Taxus canadensis.

Animal and marine sources: Ponasterone A is also a naturally occurring ecdysteroid in certain invertebrates. Several crab species contain ponasterone A as a major ecdysteroid — specifically the 25-deoxy analogue of 20E — because their molting glands produce 25-deoxyecdysone due to a low level of activity of the enzyme responsible for 25-hydroxylation; these crabs contain a mixture of PonA and 20E. Ponasterone A has been tentatively identified as the apolar ecdysteroid present in developing embryos of the blue crab, Callinectes sapidus, and also in the serum of land crabs, Gecarcinus lateralis, in the late premolt stages. Ponasterone A has also been found in Thermobia, a primitive insect. More recently, ponasterone A has been isolated from the Arctic bryozoan Alcyonidium gelatinosum, representing the first time a ponasterone had been isolated from a bryozoan.

1.4 Common Forms and Preparations

Ponasterone A is primarily available in the scientific and commercial marketplace as a highly purified research-grade compound rather than a consumer dietary supplement sold under that name. Reference-standard ponasterone A is commercially available at a purity of ≥95% by HPLC from specialized chemical suppliers. It appears in the broader context of the ecdysteroid supplement market; liquid chromatography–mass spectrometry (LC-MS) methods have been developed and validated for the simultaneous detection and quantification of 20-hydroxyecdysone, turkesterone, and ponasterone in both plant sources and dietary supplement products. A wide range of ecdysteroid-containing herbal extracts are available worldwide as food supplements. When present in such products, ponasterone A is typically a minor component rather than the primary labeled ingredient. Purified ponasterone A intended for laboratory use is supplied as a solid or dissolved in dimethyl sulfoxide (DMSO).

2. Traditional and Historical Use

2.1 Discovery Context and Early Scientific Investigation

Ponasterone A does not have a documented history of isolated traditional use as a named medicinal substance, primarily because it was not chemically characterized until 1966. However, it falls within the broader tradition of phytoecdysteroid-containing plants, many of which have long histories of medicinal use in East Asian, Central Asian, and Russian folk medicine systems.

The broader class of ecdysteroid-containing plants does have a rich, if indirect, history of traditional use. Early studies on phytoecdysteroids in the Soviet Union were undertaken to obtain toxicological and safety data for mammals exposed to these agents, revealing that they are nontoxic and that they stimulated protein synthesis; the next phase, up to about 1984, involved important studies indicating a wide diversity of essentially positive biological activities — anabolic, adaptogenic, wound healing, antidiabetic, hepatoprotective, and anti-inflammatory — largely published in Russian and largely ignored in the USA and Europe.

It was when it became apparent in the mid-1980s that ecdysteroids, in the form of the "Russian Secret," were being used with the belief that they improved the performance of sportsmen and women by increasing muscle mass, stamina, recovery from injury, and mental attitude that pharmaceutical and medical interest in these molecules began to grow.

Plants of the genus Podocarpus — the primary botanical sources of ponasterone A — are used in traditional medicine in East Asian regions, though these uses are associated with the whole plant or its extracts rather than with isolated ponasterone A specifically. The yew species Taxus cuspidata, also a source of ponasterone A, has a long history of traditional use in Japan and China, though again those uses relate to the plant's diverse phytochemical composition rather than to ponasterone A as an isolated constituent. Because the ponasterones were only characterized as a chemical class in 1966, no traditional medicinal system could have consciously selected or prepared them as individual active molecules.

3. Key Constituents and Active Compounds

3.1 Chemical Structure and Related Compounds

Ponasterone A is itself the active constituent of interest rather than a crude extract containing multiple phytochemicals. Its structure is closely related to but distinct from the other major ecdysteroids with which it is typically grouped for comparative purposes. Ecdysterone (2β,3β,14α,20β,22R,25-hexahydroxy-5β-cholest-7-en-6-one) differs from ponasterone A (2β,3β,14α,20β,22R-pentahydroxy-5β-cholest-7-en-6-one) in possessing an additional hydroxyl group at position 25.

The ponasterone series itself encompasses several structural variants: these include ponasterone A, ponasterone B, ponasterone C, and ponasterone D, as well as semisynthetic analogs such as 26-iodoponasterone A. Within the broader class, ponasterone A is notable for its exceptional receptor-binding potency. Among the many structural analogs of 20-hydroxyecdysone that exist in nature, the plant-derived ponasterone A is the most potent, and PoA has a higher affinity for the 20E nuclear receptor, composed of the ecdysone receptor (EcR) and Ultraspiracle proteins, than 20E itself.

3.2 Mechanisms of Action

3.2.1 Ecdysone Receptor (EcR) Binding

The primary and best-documented mechanism by which ponasterone A exerts biological effects — particularly in invertebrate systems and as a research tool — is through direct, high-affinity binding to the ecdysone receptor (EcR). The EcR is a member of the steroid hormone receptor superfamily and has five modular domains: A/B (transactivation), C (DNA binding, heterodimerization), D (hinge, heterodimerization), E (ligand binding, heterodimerization, and transactivation), and F (transactivation).

The ecdysone-inducible gene switch is a useful tool for modulating gene expression in mammalian cells and transgenic animals; researchers have identified plant-derived inducers as well as certain classes of insecticides that increase the versatility of this gene regulation system. To exploit the pharmacokinetics of steroids while eluding the potential complications of using a mammalian hormone as the inducer, an inducible system was developed based on the insect steroid ecdysone and the nuclear receptor that mediates its effects; in its advanced format, a chimeric protein composed of the VP16 activation domain fused to an ecdysone receptor with altered DNA-binding specificity heterodimerizes with the retinoid X receptor (RXR) and binds a unique synthetic response element not recognized by natural nuclear hormone receptors.

Ponasterone A is a potent regulator of gene expression in cells and transgenic animals, enabling reporter genes to be turned on and off rapidly. Phytoecdysteroids share the favorable pharmacokinetics of steroids but are inert in mammals in the sense that they do not bind mammalian nuclear hormone receptors governing reproduction or adrenal function. The first version of the EcR-based gene switch used Drosophila melanogaster EcR (DmEcR) and Mus musculus RXR (MmRXR), and showed that these receptors in the presence of ponasterone A transactivate reporter genes in mammalian cell lines and transgenic mice.

3.2.2 Differential Transcriptional Profile Relative to 20-Hydroxyecdysone

Although ponasterone A and 20-hydroxyecdysone both act through EcR, their genome-wide transcriptional profiles are markedly different. Genome-wide microarray analysis of Drosophila Kc167 cells treated with 20E or PoA revealed that far more genes are regulated by PoA than by 20E (256 vs. 148, respectively), and that there is very little overlap between the transcriptional responses to each hormone. While these two compounds are structurally very similar, many more genes related to various aspects of development appear to be significantly induced by 20E than by PoA; more specifically, the most strongly enriched functional terms are associated with genes down-regulated by PoA relative to 20E, including those annotated to developmental process, cell differentiation, gamete generation, anatomical structure development, organelle organization and biogenesis, neuron development, and induction of programmed cell death.

Paradoxically, PonA is much more active than 20E in many bioassays using insect species including Drosophila, although those organisms do not naturally produce this molecule. This greater potency in bioassays is attributable to the higher affinity of PonA for the EcR ligand-binding domain rather than to a broader range of transcriptional targets.

3.2.3 PI3K/Akt Pathway and Protein Synthesis in Mammals

In mammalian systems, ponasterone A (along with other phytoecdysteroids) has been investigated for effects on protein synthesis mediated through intracellular signaling pathways rather than nuclear ecdysone receptors per se. The stimulation of protein synthesis by phytoecdysteroids in muscle cells was inhibited by a phosphoinositide kinase-3 inhibitor, which suggests a PI3K-mediated mechanism. The stimulatory effect operates at the level of translation, involving the phosphorylation of the p70S6K ribosomal protein, at the end of a cascade involving the Akt/PkB protein kinase — a pathway also used by IGF-1 to stimulate protein synthesis.

3.2.4 Estrogen Receptor Involvement

More recent work in the ecdysteroid field has identified estrogen receptor beta (ERβ) as a potential mediator of the anabolic effects of this class. Emerging evidence indicates that, unlike traditional anabolic steroids that act primarily via the androgen receptor (AR), ecdysterone's anabolic effects may be mediated through estrogen receptors (ERs), particularly estrogen receptor beta (ERβ). It has been shown that 20-hydroxyecdysone, the ecdysteroid most commonly administered to humans either naturally through food or as a supplement, mediates its anabolic activity through interaction with estrogen receptor β. While this finding has been most extensively documented for ecdysterone, it is considered relevant for structurally related ecdysteroids including ponasterone A, though direct mechanistic data for PonA specifically at ERβ remain limited in the published literature.

Importantly, when considering ecdysteroid molecules in three dimensions, they show striking differences from vertebrate sex or adrenal steroids, and their full cholesterol side chain most probably prevents any binding to the receptors of vertebrate hormones.

3.2.5 Role as Anti-Herbivory Defense Molecule in Plants

In plants, ponasterone A and related phytoecdysteroids serve an ecological rather than hormonal function. Ecdysteroids are found in a wide variety of plants; phytoecdysteroids are often present in concentrations surpassing those expected of hormonal molecules, and they are widely recognized to serve as anti-feeding agents against insect herbivores. As an arthropod hormone controlling molting, ponasterone A is known to act as an allelochemical when produced by plants. In the Arctic bryozoan Alcyonidium gelatinosum, ponasterone A was produced in concentrations surpassing those expected of hormonal molecules, indicating its function as a defense molecule against molting predators.

4. Scientific Evidence by Area of Use

4.1 Use as a Research Tool: Ecdysone-Inducible Gene Switch

The most extensively documented and experimentally well-validated application of purified ponasterone A is as a ligand for EcR-based inducible gene expression systems in biomedical research. This represents a highly specialized scientific use rather than a health supplement application per se.

Ponasterone A is a potent regulator of gene expression in cells and transgenic animals, enabling reporter genes to be turned on and off rapidly; a number of nonsteroidal insecticides have also been identified that activate the ecdysone system. Tightly regulated inducible gene expression systems or "gene switches" are useful for various applications such as gene therapy, large-scale production of proteins in cells, cell-based high-throughput screening assays, functional genomics, and regulation of traits in transgenic plants and animals.

Pharmacokinetic analysis of ponasterone A, identified through screening ecdysteroids from local plants, demonstrated sustained release and transgene expression; among ecdysteroids tested, muristerone A and ponA are good inducers, whereas 20-hydroxyecdysone and inokosterone are very poor activators. The evidence base for this application is strong in the sense that it is well-replicated across numerous independent laboratories; however, it is a laboratory research tool context, not a human therapeutic or supplement context.

Evidence strength: Robust, replicated, in vitro and transgenic animal data. The use as a gene-switch ligand is among the strongest evidence categories for any ecdysteroid, but it concerns a laboratory tool rather than a human health application.

4.2 Skeletal Muscle Protein Synthesis (Anabolic Activity)

Ponasterone A has been included alongside other phytoecdysteroids in studies examining potential anabolic effects in muscle tissue.

In vitro evidence: Stimulation of protein synthesis by up to 20% in mouse and human skeletal muscle cells by ecdysteroids — specifically 20-hydroxyecdysone, polypodine B, and ponasterone — has been demonstrated (Gorelick-Feldman et al., 2008). This study by Gorelick-Feldman and colleagues, published in the Journal of Agricultural and Food Chemistry, developed an in vitro cellular assay of protein synthesis using C2C12 murine myotubes and human primary myotubes, and found that phytoecdysteroids increased protein synthesis by up to 20%; in vivo, ecdysteroids increased rat grip strength; ecdysteroid-containing plant extracts produced similar results; and the effect was inhibited by a phosphoinositide kinase-3 inhibitor, suggesting a PI3K-mediated mechanism.

Ponasterone A was one of the compounds tested in this study but was not the sole or primary subject of analysis. Most of the broader pre-clinical anabolic evidence base — including effects on grip strength, muscle fiber size, and resistance to fatigue — has used 20-hydroxyecdysone (20E) as the primary test compound, with the mechanistic evidence being considered largely applicable across structurally similar ecdysteroids.

Evidence strength: For ponasterone A specifically, the anabolic evidence is preliminary and limited to in vitro data. No controlled clinical trials in humans have evaluated ponasterone A specifically for anabolic or performance-enhancing outcomes. The broader body of evidence for the ecdysteroid class as anabolic agents comes predominantly from studies of 20-hydroxyecdysone and ecdysterone, not ponasterone A. One study in sedentary aging mice found that phytoecdysteroids did not produce anabolic effects on skeletal muscle, illustrating that results are not uniform across experimental models. The evidence overall for ponasterone A specifically as an anabolic agent in humans must be characterized as absent at the clinical level and preliminary at the preclinical level.

4.3 Genome-Wide Transcriptional Effects (Insect/Model Organism Research)

A genome-wide examination of the transcriptional response to ecdysteroids in Drosophila melanogaster compared 20-hydroxyecdysone to its plant-derived structural analog ponasterone A; among the structural analogs of 20E that exist in nature, the plant-derived ponasterone A is the most potent.

Comparison of the genome-wide transcriptional response to 20E to its plant-derived structural analog ponasterone A revealed a large difference in the transcriptional targets of these molecules; while these two compounds are structurally very similar, many more genes related to various aspects of development appear to be significantly induced by 20E than by PoA. The genes not induced by PoA include GO terms such as developmental process, cell differentiation, gamete generation, anatomical structure development, organelle organization and biogenesis, neuron development, and induction of programmed cell death.

Evidence strength: Robust at the molecular/model-organism level (Drosophila cell culture, BMC Genomics, 2011). The transcriptional data are well-characterized but do not translate directly to human health outcomes.

4.4 Broad-Spectrum Pharmacological Effects Attributed to Phytoecdysteroids

Within the wider ecdysteroid literature, pontasterone A is discussed as a member of a class exhibiting a range of biological activities. Phytoecdysteroids are apparently non-toxic to mammals, and a wide range of beneficial pharmacological activities — including adaptogenic, anabolic, anti-diabetic, hepatoprotective, immunoprotective, wound-healing, and perhaps even anti-tumor activities — is claimed for them. Phytoecdysteroids have been known for their numerous bioactivities relating to their broad-spectrum general health-promoting effects and numerous beneficial effects on mammals, which include anabolic, adaptogenic, antidiabetic, hypolipidemic, and hepatoprotective effects.

It must be emphasized, however, that the large majority of this evidence applies to ecdysteroids as a class — principally to 20-hydroxyecdysone and ecdysterone — rather than to ponasterone A specifically. Most published studies on adaptogenic, antidiabetic, hepatoprotective, and wound-healing properties have used other ecdysteroids, plant extracts standardized for 20-hydroxyecdysone, or crude ecdysteroid-containing plant extracts. There is no identified clinical trial exclusively evaluating ponasterone A for these endpoints in humans.

4.5 Anti-Insect / Ecophysiological Applications

Ecdysteroids are arthropod steroid hormones controlling molting (ecdysis), development, and reproduction through interaction with ecdysteroid receptors. Ponasterone A, by virtue of its high receptor-binding affinity, has been extensively used in academic and applied entomological research as a reference compound (positive control) in receptor-binding assays. In reporter gene assays for insect-molting hormone activity, compounds are tested at concentrations of 0.1 or 1 μM; ponasterone A is used as the standard positive control, and dimethyl sulfoxide (DMSO) as the negative control. This is a well-established analytical and research application, not a health or supplement use.

5. Body Systems and Health Areas of Association

5.1 Musculoskeletal System

The most extensively studied pharmacological domain for ponasterone A and its ecdysteroid relatives in mammals is skeletal muscle. The compound's ability to stimulate protein synthesis in muscle cells via the PI3K/Akt/mTOR cascade, with additional potential involvement of ERβ signaling, has made it of interest in the context of muscle anabolism, sarcopenia, and sports nutrition. The unique mode of action of ecdysteroids indicates their potential as orphan drugs to treat conditions associated with muscle atrophy or injury.

5.2 Endocrine System (Insect vs. Mammalian)

In insects and crustaceans, ponasterone A functions as a bona fide steroid hormone. In mammals, the picture is more complex. Ecdysteroids are not toxic to vertebrates: they have a very low toxicity, they are not hypertensive, and, in spite of their anabolic action, they would have neither androgenic nor oestrogenic (or anti-oestrogenic) effects; they induce no virilization and do not induce significant changes in castrated animals. No mammalian ortholog of the insect ecdysone receptor has been definitively identified as a high-affinity binding partner for PonA under physiological conditions.

5.3 Gene Regulatory/Biotechnology Applications

Ponasterone A is uniquely associated with the ecdysone-inducible gene regulation system. The EcR-based gene switch is being developed for use in various applications including gene therapy, expression of proteins in cell lines, and cell-based drug discovery assays. Its role in this domain spans multiple organ systems depending on the specific transgenic or gene therapy application under study.

5.4 Immune and Adaptogenic Effects

Phytoecdysteroids including ponasterone class compounds have been associated in the research literature with adaptogenic, wound healing, antidiabetic, hepatoprotective, and anti-inflammatory activities. These associations are based largely on Soviet-era and subsequent Russian-language research on crude ecdysteroid-containing plant extracts and on 20-hydroxyecdysone specifically, and should not be attributed to ponasterone A in isolation without specific supporting evidence.

6. Dosage Forms and Reported Dosages

6.1 Research-Grade Forms

Ponasterone A is not currently marketed as a standalone consumer dietary supplement with an established recommended dose. In research contexts, it is supplied as a purified solid or in DMSO solution. Reference-grade ponasterone A is commercially available with a purity of ≥95% by HPLC.

6.2 Dosages in Published Studies

In the landmark gene-switch studies published by the Bhatt, No, and Christopherson groups in PNAS, ponasterone A was applied at concentrations in the nanomolar to low-micromolar range to mammalian cell lines and transgenic mice to induce expression of reporter genes. The gene regulation properties of ponasterone A were examined in cell culture and in newly developed strains of ecdysone-system transgenic mice, where ponasterone A proved to be a potent regulator enabling reporter genes to be turned on and off rapidly.

In the Gorelick-Feldman et al. (2008) study on protein synthesis in muscle cells, ponasterone A was tested as one of a panel of ecdysteroids in in vitro conditions alongside 20-hydroxyecdysone and polypodine B; specific doses for ponasterone A in that publication were not separately reported in the accessible excerpt.

In Drosophila transcriptomics research: researchers aimed to characterize the transcriptional response to 20E and PoA in Drosophila Kc cells; genome-wide microarray analysis revealed that far more genes are regulated by PoA than by 20E (256 vs. 148, respectively). Concentrations used in that study included comparison with 0.5 μM 20E as a reference point.

In insect hormone receptor bioassays: compounds including ponasterone A are typically tested at concentrations of 0.1 or 1 μM in reporter gene assays, where PonA serves as the positive control reference.

No human clinical dosing data for ponasterone A specifically could be identified in the peer-reviewed literature searched. The related compound ecdysterone has been administered to humans at doses such as a single 50 mg dose in at least one pharmacokinetic study, but this does not apply to ponasterone A.

7. Safety Considerations

7.1 Acute Toxicity in Mammals

The acute toxicity of ecdysteroids in mammals is very low: the LD50 for 20E is above 6 g/kg. Ecdysteroids are non-toxic to mammals, with an LD50 for ingested 20-hydroxyecdysone in mice of greater than 9 g/kg and an LD50 of 6.4 g/kg for intraperitoneally injected 20E. While these figures specifically pertain to 20-hydroxyecdysone, they are frequently cited as representative of the ecdysteroid class. No specific LD50 data for ponasterone A in mammals was identified in peer-reviewed sources within the scope of this search. Ecdysteroids appear toxicologically benign, with reported LD50 > 6 g/kg in mammals.

7.2 Absence of Androgenic and Estrogenic Effects at Classical Receptors

Ecdysteroids have a very low toxicity, are not hypertensive, and, in spite of their anabolic action, would have neither androgenic nor oestrogenic (or anti-oestrogenic) effects; they induce no virilization and do not induce significant changes in castrated animals. This profile distinguishes ponasterone A and related ecdysteroids mechanistically from anabolic-androgenic steroids and conventional estrogenic compounds.

However, the more recent identification of ERβ as a potential mediator of some ecdysteroid effects introduces a nuance: emerging evidence indicates that ecdysterone's anabolic effects may be mediated through estrogen receptors, particularly estrogen receptor beta. The full physiological implications of ERβ engagement by ponasterone A in humans have not been systematically studied.

7.3 Regulatory and Doping Considerations

Ecdysterone has been included in the World Anti-Doping Agency (WADA) monitoring program, highlighting its potential impact on athletic performance and raising questions about its regulation. Unlike synthetic anabolic steroids, which are classified as controlled substances, ecdysteroids remain largely unregulated in many countries and are widely marketed as dietary supplements. Ponasterone A, because it is not commonly the primary labeled ingredient in consumer supplements, has not been the specific subject of doping regulatory action, but as a structural analog within the monitored ecdysteroid class, it may attract analytical scrutiny.

7.4 Absence of Long-Term Safety Data

Although detailed toxicological data are lacking for phytoecdysteroids broadly, their acute toxicity to mammals seems to be extremely low. No chronic toxicity studies, reproductive toxicity studies, or carcinogenicity studies specific to ponasterone A were identified in the peer-reviewed literature retrieved. Like endogenous steroid hormones and bile acids, which are biochemically related, ingested or injected phytoecdysteroids undergo a set of reactions in mammals leading to the formation of numerous metabolites, only some of which have been identified so far, and it is presently unknown whether they represent active metabolites or inactivation products.

7.5 Analytical Considerations: Presence in Supplements

Phytoecdysteroid-profiling studies applied to nutrient-rich superfoods, including kaniwa, spinach, quinoa, and asparagus, have confirmed these plants as natural sources of phytoecdysteroids; thirteen commercially available dietary supplement products labeled as containing extracts of Rhaponticum were also included in validated LC-MS screening studies for 20-hydroxyecdysone, turkesterone, and ponasterone. The presence of ponasterone A as a trace or minor component of ecdysteroid-containing supplements is therefore analytically detectable, even when products are not specifically labeled as containing it.

7.6 Caution Regarding Generalization from Related Compounds

The great majority of safety, pharmacokinetic, and clinical data available for "ecdysteroids" in humans pertains specifically to ecdysterone (20-hydroxyecdysone). These data should not be uncritically extrapolated to ponasterone A. Ponasterone A's structural difference — the absence of the 25-hydroxyl group — confers substantially greater EcR-binding affinity, and the biological consequences of this difference in human systems have not been adequately characterized. The precise molecular mechanisms underlying ecdysteroid biological activity remain poorly characterized, particularly from an in-silico perspective.

8. Summary of Evidence Characterization

• Ecdysone receptor binding and gene-switch activation: Well-established; robust in vitro and transgenic animal data. Ponasterone A is among the highest-affinity plant-derived EcR ligands known.
• Transcriptional profiling in model organisms (Drosophila): Well-established; genome-wide data published in peer-reviewed journals. Ponasterone A has a distinct transcriptional signature from 20-hydroxyecdysone.
• In vitro anabolic effects on skeletal muscle cells: Preliminary; limited to in vitro cell-culture studies in which ponasterone A was one of several test ecdysteroids. Mechanism appears to involve PI3K/Akt signaling.
• Adaptogenic, antidiabetic, hepatoprotective, and anti-inflammatory effects: Extrapolated from other ecdysteroids; no clinical data exist specifically for ponasterone A.
• Human clinical data: None identified for ponasterone A as a specific compound. All clinical evidence in the ecdysteroid field pertains to other compounds in the class.
• Safety in mammals: Acute toxicity data for the ecdysteroid class indicates very low toxicity; chronic and reproductive toxicity data specific to ponasterone A are lacking.

References

• Lachaise F et al. Ponasterone A in blue crab embryos and crustacean serum. PubMed PMID: 538780.
• Simultaneous LC–MS Profiling of Bioactive Ecdysteroids in Nutrient-Dense Plant Sources and Dietary Supplements. PMC13074551.
• Ecdysteroids: isolation, chemical transformations, and biological activity. Phytochemistry Reviews, Springer, 2022.
• Hansen KØ et al. Ponasterone A and F, Ecdysteroids from the Arctic Bryozoan Alcyonidium gelatinosum. Molecules 2018, 23(6):1481. PMC6100090.
• The phytochemical, biological, and medicinal attributes of phytoecdysteroids: An updated review. PMC8343124.
• Extraction of ponasterone A and ecdysterone from Podocarpaceae and related plants. ScienceDirect.
• Ponasterone A — an overview. ScienceDirect Topics.
• Saez E et al. Identification of ligands and coligands for the ecdysone-regulated gene switch. PNAS 2000. PMC18950.
• Identification of ligands and coligands for the ecdysone-regulated gene switch. PNAS 2000.
• Gonsalves SE et al. Genome-wide examination of the transcriptional response to ecdysteroids 20-hydroxyecdysone and ponasterone A in Drosophila melanogaster. BMC Genomics 2011;12:475. PMC3228561.
• Gonsalves SE et al. Genome-wide examination of the transcriptional response to ecdysteroids 20-hydroxyecdysone and ponasterone A in Drosophila melanogaster. BMC Genomics 2011;12:475.
• Parr MK et al. Ecdysteroids: A novel class of anabolic agents? PubMed PMID: 26060342.
• Gorelick-Feldman J et al. Phytoecdysteroids Increase Protein Synthesis in Skeletal Muscle Cells. J Agric Food Chem. 2008;56(10):3532–3537.
• Gorelick-Feldman J et al. Phytoecdysteroids increase protein synthesis in skeletal muscle cells. PubMed PMID: 18444661.
• Dinan L, Lafont R. Effects and applications of arthropod steroid hormones (ecdysteroids) in mammals. J Endocrinol. 2006;191(1):1–8.
• Lafont R, Dinan L. Practical uses for ecdysteroids in mammals including humans: an update. J Insect Sci. 2003;3:7.
• Dinan L. The Karlson Lecture. Phytoecdysteroids: What use are they? Arch Insect Biochem Physiol. 2009.
• Urinary Elimination of Ecdysterone and Its Metabolites Following a Single-Dose Administration in Humans. PMC8227119.
• Evolution of the adaptogenic concept from traditional use to medical systems. PMC7756641.
• Molecular insights into the role of Estrogen Receptor Beta in Ecdysterone Mediated Anabolic Activity. PLOS One, 2025.
• Ecdysteroid metabolism in mammals: The fate of ingested 20-hydroxyecdysone in mice and rats. ScienceDirect.
• Lawrence MM et al. Phytoecdysteroids Do Not Have Anabolic Effects in Skeletal Muscle in Sedentary Aging Mice. PMC7825148.
• A Commercial Extract of Cyanotis arachnoidea Roots as a Source of Unusual Ecdysteroid Derivatives. PMC8314276.
• Adaptogenic Properties of a Phytoecdysteroid-Rich Extract from the Leaves of Spinacia oleracea L. PMC8704498.
• Phytoecdysteroids Accelerate Recovery of Skeletal Muscle Function Following in vivo Eccentric Contraction-Induced Injury. Frontiers in Rehabilitation Sciences, 2021.